glp-1 with cv benefit Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community Treatment of High-Risk Patients with

Abbreviations GLP-1 RAs: Glucagon-like peptide-1 receptor agonists T2DM: Type 2 diabetes mellitus COPD: Chronic obstructive pulmonary disease BMI: Body mass index HbA1c: Glycated hemoglobin RR: Relative risk CI: Confidence interval RCT: Randomized controlled trial CVOT: Cardiovascular outcome trial PRISMA: Preferred reporting items for systematic reviews and meta-analyses References Zar HJ, Ferkol TW

Same protocol with one less reconstitution

These metabolic changes were supported by alterations in the gene expression of choline metabolism-related enzymes, such as choline dehydrogenase ( Chdh ), betaine-homocysteine methyltransferase ( Bhmt ), and DMG dehydrogenase ( Dmgdh ), and glycerophosphocholine phosphodiesterase 1 ( Gpcpd1 )

Hypertension (high blood pressure) Dyslipidemia (high cholesterol) Coronary artery disease Heart failure Obstructive sleep apnea (confirmed by sleep study) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Intracerebral hemorrhage (stroke) Gastroesophageal reflux disease Osteoarthritis Obesity hypoventilation syndrome/Pickwickian syndrome (confirmed by sleep study) Metabolic syndrome What is the timeline to participate in the GLP-1 Pilot Program and receive Approval by Exception